Abbott Labs Is Cheap, Not Quite Cheap Enough
Please see my latest post, in which I do a brief analysis and valuation of Abbott Labs. Abbott has been in my portfolio since early 2010. I conclude that while my previous investments have strongly outperformed the index (I added in January 2011), right now the stock is no more than 11% undervalued, which means it is not a buy for me. I also briefly analyze the Humira situation, and conclude, as many have, that AbbVie is likely to be dumped by people after the spin-off. At that time, AbbVie may present a short-term opportunity, as pessimism may well price in all of the potential downside and then some. See the full piece here.
You can follow me on Twitter, at Seeking Alpha, via my RSS feed here, or at Fool.com. Or any combination!
